News | June 21, 2026
Evonik sells Hanau pharma assets to ProChem in strategic portfolio shift
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
The sale is part of a broader strategy to streamline its asset footprint and concentrate investment on core growth areas
Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
New Tracxn report highlights growing investor confidence in automated cell therapy production, with Cellares and Ori Biotech dominating funding and regulatory milestones
Study will assess the safety and effectiveness of irreversible electroporation as a minimally invasive treatment option for benign prostatic hyperplasia (BPH)
Marketing leader behind growth of brands such as Cipladine, Maxirich, and Soak Shield takes on expanded responsibilities to drive portfolio growth and consumer engagement.
Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
Expanded indication makes Stelo the first FDA-cleared OTC CGM for children aged two years and older with diabetes or prediabetes
The decision was driven by results from the Phase III CAPItello-281 trial,
Approval is based on results from the phase 3 OASIS 4 clinical trial
MeRT becomes one of the few FDA-cleared neuromodulation therapies for PTSD, using EEG biomarkers and AI to personalize treatment for patients with treatment-resistant symptoms
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
